孟鲁司特联合布地奈德福莫特罗治疗重度哮喘的临床研究被引量：2

Clinical Research on the Treatment of Montelukast Combined with Budesonide/formoterol for Severe Asthma

在线阅读下载PDF

导出

摘要目的观察孟鲁司特联合布地奈德福莫特罗治疗重度哮喘的疗效。方法对136例重度哮喘患者进行随机对照研究,分为治疗组68例,对照组68例,治疗组用孟鲁司特联合布地奈德福莫特罗治疗,对照组吸入布地奈德福莫特罗治疗。结果两组治疗4周后,治疗组疗效优于对照组。结论孟鲁司特联合布地奈德福莫特罗治疗重度哮喘的疗效优于单用布地奈德福莫特罗治疗。 Objective To observe the curative effect of the treatment of montelukast combined with budesonide/formoterol for severe asthma. Methodss 136 cases with severe asthma were randomly divided into 2 groups： treatment group and control group,68 cases in each ; treatment group was given montelukast combined with budesonide/formoterol while inhalation of budesonide/formoterol was given to control group. Results The course of the 2 groups both lasted for 4 weeks and the curative effect in treatment group was much superior to that in control group. Conclusions The treatment of montelukast combined with budesonide/formoterol is more effective that the treatment of budesonide/formoterol only for severe asthma.

作者贾兴泽周会龙伟权刘俊静

机构地区米易县人民医院

出处《西南军医》 2008年第6期34-35,共2页 Journal of Military Surgeon in Southwest China

关键词支气管哮喘孟鲁司特布地奈德福莫特罗最大呼气流量 bronchial asthma montelukast budesonide/formoterol maximal expiratory flow

分类号 R562.25 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献7

1傅桂清,田育红,钟耀忠.舒利迭联合孟鲁司特治疗重度哮喘的临床分析[J].实用医学杂志,2007,23(13):2069-2071. 被引量：24
2董琳.白三烯受体拮抗剂的作用机制及临床应用的研究进展[J].中华儿科杂志,2005,43(4):266-268. 被引量：110
3中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南.中华结核和呼吸杂志,2008,:250-250.
4孟鲁司特临床试验协作组.白三烯受体拮抗剂孟鲁司特治疗轻中度哮喘疗效和安全性评价[J].中华结核和呼吸杂志,2002,25(3):180-181. 被引量：70
5陈琳;何权瀛.单剂量孟鲁司特或沙美特罗对运动诱发性支气管收缩的保护作用,2008(01).
6王华强,谈红.孟鲁司特钠对轻中度哮喘患者临床疗效和肺功能的影响[J].中华全科医师杂志,2004,3(1):28-28. 被引量：3
7中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案)[J].中华结核和呼吸杂志,2003,26(3):132-138. 被引量：3567

二级参考文献48

1Fregonese L, Silvestri M, Sabatini F, et al. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a Cys-LTI receptor mediated mechanism. Clin Exp Allergy, 2002, 32: 745-750.
2Braccioni F, Dorman SC, O′ byrne PM, et al. The effect of cysteinyl leukotrenes on growth of eosinophil proge from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol, 2002, 110:96-101.
3Murray J, Ward c, O′ Flaberty JT, et al. Role of leukotrenes in the regulation of human granulecyte behaviour: dissociation between agonist-induced activation and retardation of apoptosis. Br J Pharmacol, 2003, 139:388-398.
4Henderson WR Jr, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med, 2002, 165:108-116.
5Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum ECP, sIL-2R, IL-4, and sICAM-1 in children with asthma. J Allergy Clin Immunol, 2002,109: 257-263.
6Stelmach I, Grzelewski T, Stelmach W, et al. Effect of triamcinolone acetonide, montelukast, nedocromil sodium and formoterol on eosinophil blood counts, ECP serum levels and clinical progression of asthma in children. Pol Merkuriusz Lek, 2002,12:208-213.
7Strauch E, Moske O, Thoma S, et al. A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. Pediatr Res, 2003, 54:198-203.
8Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy, 1999, 29:42-51.
9Wu AY, Chik SC, Chan AW, et al. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy, 2003, 33:359-366.
10Finsnes F, Lyberg T, Christensen G, et al. Leukotriene antagonism reduces the generation of endothelin-1 and IFN-γand inhibits eosinophilic airway inflammation. Respir Med, 2002,96: 901-906.